Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb Executive Vice President Ronald Zarrella, 43, will become president and chief operating officer of the firm on Feb. 10, succeeding Thomas McDermott, 56, who is retiring in accordance with a plan announced last year. Zarrella, who also has been appointed to B&L's board of directors, joined the firm in 1985 as president of operations for the Far East, Latin America and Canada. In 1986, he was named a corporate vice president and president of subsidiary operations. He moved up to senior vice president and president of the former international division in 1987. In preparation for McDermott's retirement, Zarrella was elected executive vice president in April ("The Gray Sheet" May 4, 1992, p. 14). Following the April promotion, Zarrella began assuming some of McDermott's duties and implemented a plan to decentralize the international division. Commenting on Zarrella's appointment in a Jan. 26 announcement, B&L Chairman and CEO Daniel Gill noted that under Zarrella's direction, the company "opened 11 new subsidiary organizations in Europe, Asia and Latin America" and has seen sales outside the U.S. "grow from 26% to about 50% of consolidated revenues." Zarrella received a BS degree in electrical engineering from Worcester Polytechnic Institute in 1971 and an MBA from New York University in 1976. Prior to joining Bausch & Lomb, he held "various executive positions" with Bristol-Myers, Esmark, and Beatrice International. McDermott, a 14-year B&L veteran, became president and chief operating officer in December 1986. Highlighting McDermott's contributions to the company, Gill noted his work on restructuring the company during the early 1980s, as well as the company's conversion to total quality management.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts